Turkiye Klinikleri Journal of Health Sciences

.: REVIEW
Polifenollerden Zengin Besinler ve Hipertansiyon
Foods Rich in Polyphenols and Hypertension
Buse BAKIRa, Gizem AYTEKİN ŞAHİNa
aErciyes Üniversitesi Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümü, Kayseri, TÜRKİYE
Turkiye Klinikleri J Health Sci. 2020;5(1):135-44
doi: 10.5336/healthsci.2018-64009
Article Language: TR
Full Text
ÖZET
 Sistolik kan basıncının 140 mmHg ve diyastolik kan basıncının90 mmHg üzerinde olması olarak tanımlanan hipertansiyon, Türkiye'de önemli bir halk sağlığı problemidir. Hipertansiyonun önlenmesinde beslenme alışkanlıkları büyük önem taşımaktadır. Polifenollerden zengin çay, şarap, üzüm, kakao, zeytinyağı, soya gibi yiyecek ve içeceklerin diyette düzenli olarak tüketilmesinin kardiyovasküler sistem üzerinde koruyucu etkileri olduğu düşünülmektedir. Bu koruyucu etkiler; süperoksitanyon temizleme ve vasküler oksidatif stresi azaltma gibi fonksiyonları ile ilişkilendirilmektedir. Bu çalışmada, polifenollerden zengin besinlerin kan basıncı üzerine etkileri özetlenmiştir.

Anahtar Kelimeler: Hipertansiyon; kan basıncı; polifenoller
ABSTRACT
 Hypertension, defined as systolic blood pressure ≥140mmHg and diastolic blood pressure ≥90 mmHg, is an important publichealth problem in Turkey. Nutritional habits have a great importancein the prevention of hypertension. It is thought that regularconsumption of foods and beverages such as tea, wine, grapes, cocoa,olive oil and soy, rich in polyphenols, have protective effects on thecardiovascular system. These protective effects have been associatedwith functions such as superoxide anion scavenging and vascular oxidativestress reduction. In this review, the effects of foods rich inpolyphenols on blood pressure are summarized.

Keywords: Hypertension; blood pressure; polyphenols
REFERENCES:
  1. Bloch MJ. Worldwide prevalance of hypertension exceeds 1.3 billion. J Am Soc Hypertens. 2016;10(10):753-4. [Crossref]  [PubMed] 
  2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441-50. [Crossref]  [PubMed]  [PMC] 
  3. Öztürk A. [Epidemiology of Hypertension]. Öztürk Y, Günay O, Aykut M, editörler. Halk Sağlığı Genel Bilgiler. 1. Baskı. Kayseri: Erciyes Üniversitesi Yayınları; 2011. p.973-91.
  4. Altun B, Arici M, Nergizoğlu G, Derici U, Karatan O, Turgan C, et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the patent study) in 2003. J Hypertens. 2005;23(10):1817-23. [Crossref]  [PubMed] 
  5. Türk Hipertansiyon ve Böbrek Hastalıkları Derneği. Türk Hipertansiyon Prevalans Çalışması-PatenT2; 2012. p.64.
  6. Ganna A, Ingelsson E. 5 year mortality predictors in 498,103 UK biobank participants: a prospective population-based study. Lancet. 2015;386(9993):533-40. [Crossref] 
  7. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH CollaborativeResearch Group. N Engl J Med. 1997;336(16):1117-24. [Crossref]  [PubMed] 
  8. U.S. Department of Health and Human Services. Your Guide to Lowering Your Blood Pressure with DASH. NIH Publication No: 06-4082. ABD: National Institutes of Health; 2016. p.55.
  9. Keys A. Mediterranean diet and public health: personel reflections. Am J Clin Nutr. 1995;61(6 Suppl):1321S-3S. [Crossref]  [PubMed] 
  10. Harnden K. Hypertension. In: Gandy J, ed. Manuel of Dietetic Practice. 5th ed. West Sussex: British Dietetic Association; 2014. p.788-96.
  11. Efe D, Akça NK, Kiper S, Aydın G, Gümüş K. [Supportive methods used by the individuals with hypertension to decrease blood pressure]. Spatula DD. 2012;2(4):207-12. [Crossref] 
  12. Biçen C, Elver Ö, Erdem E, Kaya C, Karataş A, Dilek M, et al. [Herbal product use in hypertension patients]. J Exp Clin Med. 2012;29(2):109-12. [Crossref] 
  13. Bahar Z, Kizilci S, Beşer A, Besen DB, Gördes N, Ersin F, et al. [Herbal therapies used by hypertensive patients in Turkey]. Afr J Tradit Complement Altern Med. 2012;10(2):292-8. [Crossref] 
  14. Ascherio A, Hennekens C, Willett WC, Sacks F, Rosner B, Manson J et al. [Prospective Study of Nutritional Factors, Blood Pressure, and Hypertension Among US Women]. Hypertension 1996;27(5):1065-72. [Crossref]  [PubMed] 
  15. Alonso A, de la Fuente C, Martín-Arnau AM, de Irala J, Martínez JA, Martínez-González MA. Fruit and vegetable consumption is inversely associated with blood pressure in a Mediterranean population with a high vegetable-fat intake: the Seguimiento Universidad de Navarra (SUN) Study. Br J Nutr. 2004;92(2):311-9. [Crossref]  [PubMed] 
  16. Medina-Remón A, Tresserra-Rimbau A, Valderas-Martinez P, Estruch R, Lamuela-Raventos RM. Polyphenol consumption and blood pressure. In: Watson R, Preedy V, Zibadi S, eds. Polyphenols in Human Health and Disease. 1st ed. Massachusetts: Academic Press; 2014. p.971-87. [Crossref] 
  17. Qui-ones M, Miguel M, Aleixandre A. Beneficial effects of polyphenols on cardiovascular disease. Pharmacol Res. 2013;68(1):125-31. [Crossref]  [PubMed] 
  18. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 1997;37(8):693-704. [Crossref]  [PubMed] 
  19. Hügel HM, Jackson N, May B, Zhang AL, Xue CC. Polyphenol protection and treatment of hypertension. Phytomedicine. 2016;23(2):220-31. [Crossref]  [PubMed] 
  20. Bhardwaj P, Khanna D. Green tea catechins: defensive role in cardiovascular disorders. Chin J Nat Med. 2013;11(4):345-53. [Crossref] 
  21. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanism. Circ Res. 2007;100(2):158-73. [Crossref]  [PubMed] 
  22. Nantz MP, Rowe CA, Bukowski JF, Percival SS. Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. Nutrition. 2009;25(2):147-54. [Crossref]  [PubMed] 
  23. Bogdanski P, Suliburska J, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res. 2012;32(6):421-7. [Crossref]  [PubMed] 
  24. Sone T, Kuriyama S, Nakaya N, Hozawa A, Shimazu T, Nomura K, et al. Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors. Food Nutr Res. 2011;55. [Crossref]  [PubMed]  [PMC] 
  25. San Cheang W, Yuen Ngai C, Yen Tam Y, Yu Tian X, Tak Wong W, Zhang Y, et al. Black tea protects against hypertension-associated endothelial dysfunction through alleviation of endoplasmic reticulum stress. Sci Rep. 2015;5:10340. [Crossref]  [PubMed]  [PMC] 
  26. Alkerwi A, Sauvageot N, Crichton GE, Elias MF. Tea, but not coffee consumption, is associated with components of arterial pressure. the observation of cardiovascular risk factors study in Luxembourg. Nutr Res. 2015;35(7):557-65. [Crossref]  [PubMed] 
  27. Hodgson JM, Croft KD, Woodman RJ, Puddey IB, Fuchs D, Draijer R, et al. Black tea lowers the rate of blood pressure variation: a randomized controlled trial. Am J Clin Nutr. 2013;97(5):943-50. [Crossref]  [PubMed] 
  28. Greyling A, Ras RT, Zock PL, Lorenz M, Hopman MT, Thijssen DH, et al. The effect of black tea on blood pressure: a systematic review with meta-analysis of randomized controlled trials. PLoS One. 2014;9(7):e103247. [Crossref]  [PubMed]  [PMC] 
  29. Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW. Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl). 2008;195(4):569-77. [Crossref]  [PubMed] 
  30. da Silva Punto M. Tea: a new perspective on health benefits. Food Res Int. 2013;53(2):558-67. [Crossref] 
  31. Mozaffari-Khosravi H, Jalali-Khanabadi BA, Afkhami-Ardekani M, Fatehi F, Noori-Shadkam M. The effects of sour tea (Hibiscus sabdariffa) on hypertension in patients with type II diabetes. J Hum Hypertens. 2009;23(1):48-54. [Crossref]  [PubMed] 
  32. Herrera-Arellano A, Miranda-Sánchez J, Avila-Castro P, Herrera-Alvarez S, Jiménez-Ferrer JE, Zamilpa A, et al. Clinical effects produced by a standardized herbal medicinal product of hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. Planta Med. 2007;73(1):6-12. [Crossref]  [PubMed] 
  33. Mojiminiyi FB, Dikko M, Muhammad BY, Ojobor PD, Ajagbonna OP, Okolo RU, et al. Antihypertensive effect of an aqueous extract of the calyx of Hibiscus sabdariffa. Fitoterapia. 2007;78(4):292-7. [Crossref]  [PubMed] 
  34. Da-Costa-Rocha I, Bonnlaender B, Sievers H, Pischel I, Heinrich M. Hibiscus sabdariffa L.-a phytochemical and pharmacological review. Food Chem. 2014;165:424-43. [Crossref]  [PubMed] 
  35. Mojiminiyi FB, Audu Z, Etuk EU, Ajagbonna OP. Attenuation of salt-induced hypertension by aqueous calyx extract of Hibiscus sabdariffa. Niger J Physiol Sci. 2012;27(2):195-200.
  36. McKay DL, Chen CY, Saltzman E, Blumberg JB. Hibiscus sabdariffa L. tea (tisane) lowers blood pressure in prehypertensive and mildly hypertensive adults. J Nutr. 2010;140(2):298-303. [Crossref]  [PubMed] 
  37. Gurrola-Díaz CM, García-López PM, Sánchez-Enríquez S, Troyo-Sanromán R, Andrade-González I, Gómez-Leyva JF. Effects of Hibiscus sabdariffa extract powder and preventive treatment (diet) on the lipid profiles of patients with metabolic syndrome (MeSy). Phytomedicine. 2010;17(7):500-5. [Crossref]  [PubMed] 
  38. Şar S. [The place of the coffee in our healthy and social life]. Lokman Hekim Journal. 2012;2(2):35-44.
  39. Brezová V, ?lebodová A, Sta?ko A. Coffee as a source of antioxidants: an EPR study. Food Chem. 2009;114(3):859-68. [Crossref] 
  40. Tomé-Carneiro J, Larrosa M, Yá-ez-Gascón MJ, Dávalos A, Gil-Zamorano J, Gonzálvez M, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69-82. [Crossref]  [PubMed] 
  41. Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic ıntake of coffee and caffeine: a meta-analysis of randomized controlled trial. J Hypertens. 2005;23(5):921-8. [Crossref]  [PubMed] 
  42. Zhang Z, Hu G, Caballero B, Appel L, Chen L. Habitual coffee consumption and risk of hypertension: a systematic review and meta-analysis of prospective observational studies. Am J Clin Nutr. 2011;93(6):1212-9. [Crossref]  [PubMed] 
  43. Steffen M, Kuhle C, Hensrud D, Erwin PJ, Murad MH. The effect of coffee consumption on blood pressure and the development of hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30(12):2245-54. [Crossref]  [PubMed] 
  44. Suzuki A, Kagawa D, Fujii A, Ochiai R, Tokimitsu I, Saito I. Short- and long-term effects of ferulic acid on blood pressure in spontaneously hypertensive rats. Am J Hypertens. 2002;15(4 Pt 1):351-7. [Crossref] 
  45. Kozuma K, Tsuchiya S, Kohori J, Hase T, Tokimitsu I. Antihypertensive effect of green coffee bean extract on mildly hypertensive subjects. Hypertens Res. 2005;28(9):711-8. [Crossref]  [PubMed] 
  46. Suzuki A, Fujii A, Yamamoto N, Yamamoto M, Ohminami H, Kameyama A, et al. Improvement of hypertension and vascular dysfunction by hydroxyhydroquinone-free coffee in a genetic model of hypertension. FEBS Lett. 2006;580(9):2317-22. [Crossref]  [PubMed] 
  47. Ochiai R, Jokura H, Suzuki A, Tokimitsu I, Ohishi M, Komai N, et al. Green coffee bean extract improves human vasoreactivity. Hypertens Res. 2004;27(10):731-7. [Crossref]  [PubMed] 
  48. Mubarak A, Bondonno CP, Liu AH, Considine MJ, Rich L, Mas E, et al. Acute effects of chlorogenic acid on nitric oxide status, endothelial function, and blood pressure in healthy volunteers: a randomized trial. J Agric Food Chem. 2012;60(36):9130-6. [Crossref]  [PubMed] 
  49. Revuelta-Iniesta R, Al-Dujaili EAS. Consumption of green coffee reduces blood pressure and body composition by influencing 11β-HSD1 enzyme activity in healthy individuals: a pilot crossover study using green and black coffee. Biomed Res Int. 2014;9. [Crossref]  [PubMed]  [PMC] 
  50. Corti R, Flammer AJ, Hollenberg NK, Lüscher TF. Cocoa and cardiovascular health. Circulation. 2009;119(10):1433-41. [Crossref]  [PubMed] 
  51. Heiss C, Kelm M. Chocolate consumption, blood pressure, and cardiovascular risk. Eur Heart J. 2010;31(13):1554-6. [Crossref]  [PubMed]  [PMC] 
  52. Fernández-Murga L, Tarín JJ, García-Perez MA, Cano A. The impact of chocolate on cardiovascular health. Maturitas. 2011;69(4):312-21. [Crossref]  [PubMed] 
  53. Ried K, Fakler P, Stocks NP. Effect of cocoa on blood pressure. Cochrane Database Syst Rev. 2017;4:CD008893. [Crossref]  [PubMed]  [PMC] 
  54. Chaitman BR, Schmitz HH, Keen CL. Cocoa flavanols and cardiovascular health. US Cardiology. 2006;2(1):1-5.
  55. Ludovici V, Barthelmes J, Nägele MP, Enseleit F, Ferri C, Flammer AJ, et al. Cocoa, blood pressure, and vascular function. Front Nutr. 2017;4:36. [Crossref]  [PubMed]  [PMC] 
  56. Rostami A, Khalili M, Haghighat N, Eghtesadi S, Shidfar F, Heidari I, et al. High-cocoa polyphenol-rich chocolate improves blood pressure in patients with diabetes and hypertension. ARYA Atheroscler. 2015;11(1):21-9.
  57. Curtis PJ, Potter J, Kroon PA, Wilson P, Dhatariya K, Sampson M, et al. Vascular function and atherosclerosis progression after 1 y of flavonoid intake in statin-treated postmenopausal women with type 2 diabetes: a double-blind randomized controlled trial. Am J Clin Nutr. 2013;97(5):936-42. [Crossref]  [PubMed] 
  58. Medjakovic S, Jungbauer A. Pomegranate: a fruit that ameliorates metabolic syndrome. Food Funct. 2013;4(1):19-39. [Crossref]  [PubMed] 
  59. Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis. 2001;158(1):195-8. [Crossref] 
  60. Lynn A, Hamadeh H, Leung WC, Russell JM, Barker ME. Effects of pomegranate juice supplementation on pulse wave velocity and blood pressure in healthy young and middle-aged men and women. Plant Foods Hum Nutr. 2012;67(3):309-14. [Crossref]  [PubMed] 
  61. de Nigris F, Williams-Ignarro S, Botti C, Sica V, Ignarro LJ, Napoli C. Pomegranate juice reduces oxidized low-density lipoprotein downregulation of endothelial nitric oxide synthase in human coronary endothelial cells. Nitric Oxide. 2006;15(3):259-63. [Crossref]  [PubMed] 
  62. Ali K, Maltese F, Choi YH, Verpoorte R. Metabolic constituents of grapevine and grape-derived products. Phytochem Rev. 2010;9(3):357-78. [Crossref]  [PubMed]  [PMC] 
  63. Nassiri-Asl M, Hosseinzadeh H. Review of the pharmacological effects of vitis vinifera (Grape) and its bioactive compounds. Phytother Res. 2009;23(9):1197-204. [Crossref]  [PubMed] 
  64. Xia EQ, Deng GF, Guo YJ, Li HB. Biological activities of polyphenols from grapes. Int J Mol Sci. 2010;11(2):622-46. [Crossref]  [PubMed]  [PMC] 
  65. He F, Mu L, Yan GL, Liang NN, Pan QH, Wang J, et al. Biosynthesis of anthocyanins and their regulation in colored grapes. Molecules. 2010;15(12):9057-91. [Crossref]  [PubMed]  [PMC] 
  66. Cantos E, Espín JC, Tomás-Barberán FA. Varietal differences among the polyphenol profiles of seven table cultivars studied by LC-DAD-MS-MS. J Agric Food Chem. 2002;50(20):5691-6. [Crossref]  [PubMed] 
  67. Barona J, Aristizabal JC, Blesso CN, Volek JS, Fernandez ML. Grape polyphenols reduce blood pressure and ıncrease flow-mediated vasodilation in men with metabolci syndrome. J Nutr. 2012;142(9):1626-32. [Crossref]  [PubMed] 
  68. Vaisman N, Niv E. Daily consumption of red grape cell powder in a dietary dose improves cardiovascular parameters: a double blind, placebo-controlled, randomized study. Int J Food Sci Nutr. 2015;66(3):342-9. [Crossref]  [PubMed] 
  69. Terauchi M, Horiguchi N, Kajiyama A, Akiyoshi M, Owa Y, Kato K, et al. Effects of grape seed proanthocyanidin extract on menopausal symptoms, body composition, and cardiovascular parameters in middle-aged women: a randomized, double-blind, placebo-controlled pilot study. Menopause. 2014;21(9):990-6. [Crossref]  [PubMed] 
  70. Brown L, Kroon PA, Das DK, Das S, Tosaki A, Chan V, et al. The biological responses to resveratrol and other polyphenols from alcoholic beverages. Alcohol Clin Exp Res. 2009;33(9):1513-23. [Crossref]  [PubMed]  [PMC] 
  71. Szajdek A, Borowska EJ. Bioactive compounds and health-promoting properties of berry fruits: a review. Plant Foods Hum Nutr. 2008;63(4):147-56. [Crossref]  [PubMed] 
  72. de Lorimier AA. Alcohol, wine, and health. Am J Surg. 2000;180(5):357-61. [Crossref] 
  73. De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, et al. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights ınto the cardioprotective effect of certain nutriments. J Am Coll Cardiol. 1996;28(5):1103-8. [Crossref] 
  74. Flesch M, Schwarz A, Böhm M. Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am J Physiol. 1998;275(4 Pt 2):H1183-90. [Crossref]  [PubMed] 
  75. Garcia-Alonso M, Minihane AM, Rimbach G, Rivas-Gonzalo JC, de Pascual-Teresa S. Red wine anthocyanins are rapidly absorbed in humans and affect monocyte chemoattractant protein 1 levels and antioxidant capacity of plasma. J Nutr Biochem. 2009;20(7):521-9. [Crossref]  [PubMed] 
  76. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M, et al. Sirtuin activators mimic caloric restriction and delay aging in metazoans. Nature. 2004;430(7000):686-9. [Crossref]  [PubMed] 
  77. Bello AT, Bora NS, Lange LG, Bora PS. Cardioprotective effects of alcohol: mediation by human vascular alcohol dehydrogenase. Biochem Biophys Res Commun. 1994;203(3):1858-64. [Crossref]  [PubMed] 
  78. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319(7224):1523-8. [Crossref]  [PubMed]  [PMC] 
  79. Matsuo S, Nakamura Y, Takahashi M, Ouchi Y, Hosoda K, Nozawa M, et al. Effect of red wine and ethanol on production of nitric oxide in healthy subjects. Am J Cardiol. 2001;87(8):1029-31. [Crossref] 
  80. Draijer R, de Graaf Y, Slettenaar M, de Groot E, Wright CI. Consumption of a polyphenol-rich grape-wine extract lowers ambulatory blood pressure in mildly hypertensive subjects. Nutrients. 2015;7(5):3138-53. [Crossref]  [PubMed]  [PMC] 
  81. Covas MI, de la Torre R, Fitó M. Scientific evidence of the benefits of virgin olive oil for human health. Medicina Balear. 2014;29(2):39-46.
  82. Food & Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO). Standard for Olive Oils and Olive Pomace Oils. Codex Stan 33-1981. Codex Alimentarius; 2015. p.9.
  83. Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, Sanchez-Rovira P, Ramirez-Tortosa MC. Hydroxytyrosol: from laboratory investigations to future clinical trials. Nutr Rev. 2010;68(4):191-206. [Crossref]  [PubMed] 
  84. Bulotta S, Celano M, Lepore SM, Montalcini T, Pujia A, Russo D. Beneficial effects of the olive oil phenolic components oleuropein and hydroxytyrosol: focus on protection against cardiovascular and metabolic diseases. J Transl Med. 2014;3(12):219. [Crossref]  [PubMed]  [PMC] 
  85. Hohmann CD, Cramer H, Michalsen A, Kessler C, Steckhan N, Choi K, et al. Effects of high phenolic olive oil on cardiovascular risk factors: a systematic review and meta-analysis. Phytomedicine. 2015;22(6):631-40. [Crossref]  [PubMed] 
  86. Schwingshackl L, Christoph M, Hoffmann G. Effects of olive oil on markers of inflammation and endothelial function-a systematic review and meta-analysis. Nutrients. 2015;7(9):7651-75. [Crossref]  [PubMed]  [PMC] 
  87. Liu ZM, Ho SC, Chen YM, Tomlinson B, Ho S, To K, et al. Effect of whole soy and purified daidzein on ambulatory blood pressure and endothelial function a 6-month double-blind, randomized controlled trial among Chinese postmenopausal women with prehypertension. Eur J Clin Nutr. 2015;69(10):1161-8. [Crossref]  [PubMed] 
  88. Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S. Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: The Japan Public Health Center-Based (JPHC) study cohort I. Circulation. 2007;116(22):2553-62. [Crossref]  [PubMed] 
  89. Yang G, Shu XO, Jin F, Zhang X, Li HL, Li Q, et al. Longitudinal study of soy food intake and blood pressure among middle-aged elderly Chinese women. Am J Clin Nutr. 2005;81(5):1012-7. [Crossref]  [PubMed] 
  90. Mann GE, Rowlands DJ, Li FY, de Winter P, Siow RC. Activation of endothelial nitric oxide synthase by dietary isoflavones: role of NO in Nrf2-mediated antioxidant gene expression. Cardiovasc Res. 2007;75(2):261-74. [Crossref]  [PubMed] 
  91. García-Martínez MC, Hermenegildo C, Tarín JJ, Cano A. Phytoestrogens increase the capacity of serum to stimulate prostacyclin release in human endothelial cells. Acta Obstet Gynecol Scand. 2003;82(8):705-10. [Crossref]  [PubMed] 
  92. Li SH, Liu XX, Bai YY, Wang XJ, Sun K, Chen JZ, et al. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am J Clin Nutr. 2010;91(2):480-6. [Crossref]  [PubMed] 
  93. Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Fong DY, et al. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischemic stroke. Eur Heart J. 2008;29(22):2800-7. [Crossref]  [PubMed] 
  94. Atteritano M, Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, et al. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007;92(8):3068-75. [Crossref]  [PubMed] 
  95. Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V, et al. Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: a follow-up study. Nutr Metab Cardiovasc Dis. 2010;20(5):332-40. [Crossref]  [PubMed] 
  96. D'Anna R, Cannata ML, Marini H, Atteritano M, Cancellieri F, Corrado F, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause. 2009;16(2):301-6. [Crossref]  [PubMed] 
  97. Squadrito F, Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N, et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med. 2003;114(6):470-6. [Crossref] 
  98. Irace C, Marini H, Bitto A, Altavilla D, Polito F, Adamo EB, et al. Genistein and endothelial function in postmenopausal women with metabolic syndrome. Eur J Clin Invest. 2013;43(10):1025-31. [Crossref]  [PubMed] 
  99. Roghani M, Vaez Mahdavi MR, Jalali-Nadoushan MR, Baluchnejadmojarad T, Naderi G, Roghani-Dehkordi F, et al. Chronic administration of daidzein, a soybean isoflavone, improves endothelial dysfunction and attenuates oxidative stress in streptozotocin-induced diabetic rats. Phytother Res. 2013;27(1):112-7. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com